ADVFN - ニュース

S&P 500

5,277.51

0.80%

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

登録

該当コードがありません。

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/01	21 : 00	Business Wire	Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024
2024/06/01	21 : 00	GlobeNewswire Inc.	Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024	NASDAQ:MOLN	Molecular Partners AG
2024/06/01	21 : 00	GlobeNewswire Inc.	CryptoHeap Targets Top Position in Crypto Staking Industry Before Bull Run Concludes
2024/06/01	21 : 00	Business Wire	Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)	NYSE:PFE	Pfizer Inc
2024/06/01	21 : 00	Business Wire	KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer	NYSE:BMY	Bristol Myers Squibb Co
2024/06/01	21 : 00	Business Wire	Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers	NYSE:RCUS	Arcus Biosciences Inc
2024/06/01	21 : 00	GlobeNewswire Inc.	Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting	NASDAQ:KYMR	Kymera Therapeutics Inc
2024/06/01	21 : 00	Business Wire	Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma	NYSE:PFE	Pfizer Inc
2024/06/01	21 : 00	Business Wire	Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA	NASDAQ:SMMT	Summit Therapeutics Inc
2024/06/01	21 : 00	Business Wire	Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers	NYSE:RCUS	Arcus Biosciences Inc
2024/06/01	21 : 00	Business Wire	Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
2024/06/01	21 : 00	GlobeNewswire Inc.	OkayCoin CEO Releases Key Strategies to Maximize Investor Returns on Staking Platform
2024/06/01	21 : 00	Business Wire	Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers	NASDAQ:GILD	Gilead Sciences Inc
2024/06/01	21 : 00	GlobeNewswire Inc.	Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer	NASDAQ:PPBT	Purple Biotech Ltd
2024/06/01	21 : 00	Business Wire	Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers	NASDAQ:GILD	Gilead Sciences Inc
2024/06/01	21 : 00	Business Wire	Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma	NYSE:TAK	Takeda Pharmaceutical Company Ltd
2024/06/01	21 : 00	GlobeNewswire Inc.	Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response	NASDAQ:IMCR	Immunocore Holdings PLC
2024/06/01	20 : 30	Cointelegraph	Uniswap Foundation postpones vote on incentives	COIN:UNIUSD	Uniswap
2024/06/01	20 : 24	PR Newswire (Canada)	Le loyer étudiant moyen a augmenté de 20% en trois ans à Québec
2024/06/01	20 : 10	PR Newswire (US)	Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
2024/06/01	20 : 01	GlobeNewswire Inc.	Il documentario Life at the Yellow River Delta vince ai Telly Awards
2024/06/01	20 : 00	GlobeNewswire Inc.	Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib	NASDAQ:CGEM	Cullinan Therapeutics Inc
2024/06/01	20 : 00	PR Newswire (Canada)	/R A P P E L -- Avis aux médias - Itinéraire du premier ministre pour le samedi 1 juin 2024/
2024/06/01	20 : 00	PR Newswire (Canada)	Demain, dimanche 2 juin, le Festival Go vélo Montréal convie les représentants des médias au départ du 39e Tour de l'Île de Montréal !
2024/06/01	20 : 00	PR Newswire (Canada)	/R E P R I S E -- Horaire de garde médias du cabinet de la mairesse et du comité exécutif/
2024/06/01	20 : 00	PR Newswire (Canada)	/R E M I N D E R -- Media Advisory - Prime Minister's itinerary for Saturday, June 1, 2024/
2024/06/01	19 : 20	Alliance News	Israel insists on Hamas "destruction" as part of plan to end Gaza war
2024/06/01	19 : 17	Alliance News	PRESS: Ackman's Pershing Square Capital plans IPO, USD1 billion raise
2024/06/01	19 : 09	Cointelegraph	Crypto community backs CZ amid prison term	COIN:FOURRUSD	Four
2024/06/01	19 : 00	NEWSBTC	Ethereum Spot ETF: Franklin Templeton Launches Fee War With 0.19% Offer	COIN:ETHUSD	Ethereum